G&A at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's G&A?
- Ligand Pharmaceuticals (LGND) reported G&A of $20.84M in Q1 2026.
- How has Ligand Pharmaceuticals's G&A changed year-over-year?
- Ligand Pharmaceuticals's G&A increased by 10.8% year-over-year, from $18.8M to $20.84M.
- What is the long-term trend for Ligand Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's G&A has grown at a 18.6% compound annual growth rate (CAGR), from $46.79M to $92.45M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.